News Vaxcyte's pneumococcal jab exceeds expectations Shares in Vaxcyte have rocketed on phase 3 trial data for its pneumococcal vaccine VAX-31 that suggests it could take on rivals from Pfizer and MSD.
News AI spots drugs that may be repurposed for priority pathogen Researchers have used AI algorithms to sift through thousands of drug molecules and identify some with activity against problem pathogen S pneumoniae.
News MSD takes on Pfizer's Prevnar with new Capvaxive approval MSD has claimed new territory for pneumococcal vaccines after getting FDA approval for use of Capvaxive in vulnerable children aged two to 17.
News Pfizer takes 25-valent Prevnar follow-up into phase 3 Pfizer has upped the ante in the increasingly competitive market for pneumococcal vaccines with new data on a 25-valent candidate.
News Sanofi takes SK Bio-partnered pneumococcal shot into phase 3 Sanofi has moved ahead with plans to challenge Pfizer and MSD for a piece of the market for pneumococcal vaccines.
News Vaxcyte's pneumococcal vaccine win points to Prevnar battle Vaxcyte's new pneumococcal vaccine may only have phase 1/2 results behind it, but analysts are already predicting it could be a major competitor to rival shots from Pfizer and MSD.
News Novartis raises forecasts for three key growth products Novartis raises sales expectations for three growth products – Kesimpta, Scemblix, and Leqvio – by $4bn as it sets a 5% midterm revenue growth target.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.